X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated for the treatment of cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Details:
Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor, but does not bind to the body's other hormone receptors. It is being evaluated for the treatment of cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
CORT113176 (dazucorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor (GR), but does not bind to the body’s other hormone receptors and is being developed for amyotrophic lateral sclerosis (ALS).
Lead Product(s): Dazucorilant
Therapeutic Area: Neurology Product Name: CORT113176
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated in combination with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated for the treatment of adrenal cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
